News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
FDA to Meet on Long-Lasting Zyprexa
January 9, 2008
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
WASHINGTON -The Food and Drug Administration has scheduled a meeting next month to review the safety and effectiveness of a long-acting version of Eli Lilly & Co.'s schizophrenia drug.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Postmarket research
Regulatory
Eli Lilly and Company
Food and Drug Administration (FDA)
MORE ON THIS TOPIC
Approvals
Milestone’s Long Regulatory Road Ends in Approval for Cardamyst
December 15, 2025
·
2 min read
·
Tristan Manalac
COVID-19
Prasad’s Claim of 10 Pediatric Deaths From COVID-19 Shots Overblown: Report
December 15, 2025
·
2 min read
·
Tristan Manalac
Clinical research
‘Au Revoir TIGIT’: Gilead, Arcus Cut Gastro Cancer Drug After Late-Stage Failure
December 12, 2025
·
3 min read
·
Annalee Armstrong
Vaccines
FDA Plans Black Box Warning for COVID-19 Vaccines: Report
December 12, 2025
·
3 min read
·
Heather McKenzie
